Company registration number SC259899 (Scotland)
APS BIOCONTROL LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
APS BIOCONTROL LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
APS BIOCONTROL LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
20,145
33,668
Current assets
Stocks
106,499
228,328
Debtors
5
142,771
63,117
Cash at bank and in hand
1,054,931
848,784
1,304,201
1,140,229
Creditors: amounts falling due within one year
6
(92,281)
(59,932)
Net current assets
1,211,920
1,080,297
Total assets less current liabilities
1,232,065
1,113,965
Provisions for liabilities
(5,037)
(7,967)
Net assets
1,227,028
1,105,998
Capital and reserves
Called up share capital
127
127
Share premium account
151,450
151,450
Capital redemption reserve
31
31
Profit and loss reserves
1,075,420
954,390
Total equity
1,227,028
1,105,998
APS BIOCONTROL LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2025
31 December 2025
- 2 -

For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 19 June 2026 and are signed on its behalf by:
Dr A Blackwell
Director
Company registration number SC259899 (Scotland)
APS BIOCONTROL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
1
Accounting policies
Company information

APS Biocontrol Limited is a private company limited by shares incorporated in Scotland. The registered office is Alchemy House, 8 Tom Mcdonald Avenue, Dundee, Scotland, DD2 1NH.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Revenue

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Straight line basis over five years
Plant and equipment
Straight line basis over four years
Computers
Straight line basis over three years
Motor vehicles
Straight line basis over five years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

APS BIOCONTROL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

APS BIOCONTROL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

1.13
Government grants

Government grants are recognised at the fair value of the asset receive d or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.14
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

APS BIOCONTROL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 6 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
5
6
4
Tangible fixed assets
Leasehold improvements
Plant and equipment
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 January 2025 and 31 December 2025
4,243
255,738
13,940
32,295
306,216
Depreciation and impairment
At 1 January 2025
3,312
249,772
13,365
6,099
272,548
Depreciation charged in the year
523
5,966
575
6,459
13,523
At 31 December 2025
3,835
255,738
13,940
12,558
286,071
Carrying amount
At 31 December 2025
408
-
0
-
0
19,737
20,145
At 31 December 2024
931
5,966
575
26,196
33,668
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
42,427
35,732
Other debtors
100,344
27,385
142,771
63,117
APS BIOCONTROL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
34,768
33,581
Corporation tax
29,937
-
0
Other taxation and social security
6,987
6,749
Other creditors
20,589
19,602
92,281
59,932
7
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
70,000
120,000
2025-12-31 2025-01-01 false false false 19 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Alison Blackwell Mark Willcox Fergus McKenzie SC259899 2025-01-01 2025-12-31 SC259899 2025-12-31 SC259899 2024-12-31 SC259899 core:LeaseholdImprovements 2025-12-31 SC259899 core:PlantMachinery 2025-12-31 SC259899 core:ComputerEquipment 2025-12-31 SC259899 core:MotorVehicles 2025-12-31 SC259899 core:LeaseholdImprovements 2024-12-31 SC259899 core:PlantMachinery 2024-12-31 SC259899 core:ComputerEquipment 2024-12-31 SC259899 core:MotorVehicles 2024-12-31 SC259899 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 SC259899 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 SC259899 core:CurrentFinancialInstruments 2025-12-31 SC259899 core:CurrentFinancialInstruments 2024-12-31 SC259899 core:ShareCapital 2025-12-31 SC259899 core:ShareCapital 2024-12-31 SC259899 core:SharePremium 2025-12-31 SC259899 core:SharePremium 2024-12-31 SC259899 core:CapitalRedemptionReserve 2025-12-31 SC259899 core:CapitalRedemptionReserve 2024-12-31 SC259899 core:RetainedEarningsAccumulatedLosses 2025-12-31 SC259899 core:RetainedEarningsAccumulatedLosses 2024-12-31 SC259899 bus:Director1 2025-01-01 2025-12-31 SC259899 core:LeaseholdImprovements 2025-01-01 2025-12-31 SC259899 core:PlantMachinery 2025-01-01 2025-12-31 SC259899 core:ComputerEquipment 2025-01-01 2025-12-31 SC259899 core:MotorVehicles 2025-01-01 2025-12-31 SC259899 2024-01-01 2024-12-31 SC259899 core:LeaseholdImprovements 2024-12-31 SC259899 core:PlantMachinery 2024-12-31 SC259899 core:ComputerEquipment 2024-12-31 SC259899 core:MotorVehicles 2024-12-31 SC259899 2024-12-31 SC259899 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 SC259899 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 SC259899 bus:FRS102 2025-01-01 2025-12-31 SC259899 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 SC259899 bus:Director2 2025-01-01 2025-12-31 SC259899 bus:Director3 2025-01-01 2025-12-31 SC259899 bus:FullAccounts 2025-01-01 2025-12-31 xbrli:pure xbrli:shares iso4217:GBP